Henry Schein, Inc. (NASDAQ:HSIC) Shares Acquired by Speece Thorson Capital Group Inc.

Speece Thorson Capital Group Inc. grew its stake in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 20.0% in the third quarter, according to its most recent disclosure with the SEC. The fund owned 235,967 shares of the company’s stock after buying an additional 39,352 shares during the period. Henry Schein makes up 3.2% of Speece Thorson Capital Group Inc.’s investment portfolio, making the stock its 9th biggest holding. Speece Thorson Capital Group Inc. owned about 0.19% of Henry Schein worth $17,202,000 as of its most recent filing with the SEC.

Other large investors have also made changes to their positions in the company. SG Americas Securities LLC increased its stake in Henry Schein by 66.4% in the first quarter. SG Americas Securities LLC now owns 16,202 shares of the company’s stock valued at $1,224,000 after acquiring an additional 6,468 shares during the period. Forsta AP Fonden grew its stake in Henry Schein by 8.9% during the first quarter. Forsta AP Fonden now owns 24,500 shares of the company’s stock worth $1,850,000 after buying an additional 2,000 shares during the last quarter. Sei Investments Co. grew its stake in Henry Schein by 5.9% during the first quarter. Sei Investments Co. now owns 389,789 shares of the company’s stock worth $29,437,000 after buying an additional 21,740 shares during the last quarter. State Board of Administration of Florida Retirement System grew its stake in Henry Schein by 7.0% during the first quarter. State Board of Administration of Florida Retirement System now owns 185,054 shares of the company’s stock worth $15,089,000 after buying an additional 12,087 shares during the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. grew its stake in Henry Schein by 32.6% during the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 161,517 shares of the company’s stock worth $12,198,000 after buying an additional 39,739 shares during the last quarter. Institutional investors and hedge funds own 96.62% of the company’s stock.

Henry Schein Trading Down 0.7 %

NASDAQ HSIC traded down $0.46 during trading hours on Wednesday, hitting $67.00. The company’s stock had a trading volume of 63,022 shares, compared to its average volume of 1,348,283. The stock has a fifty day moving average of $70.40 and a 200 day moving average of $69.63. The firm has a market capitalization of $8.35 billion, a P/E ratio of 27.76, a PEG ratio of 1.96 and a beta of 0.87. Henry Schein, Inc. has a twelve month low of $63.67 and a twelve month high of $82.63. The company has a quick ratio of 0.82, a current ratio of 1.42 and a debt-to-equity ratio of 0.46.

Henry Schein (NASDAQ:HSIC) last announced its quarterly earnings results on Tuesday, November 5th. The company reported $1.22 earnings per share for the quarter, topping analysts’ consensus estimates of $1.17 by $0.05. The company had revenue of $3.17 billion for the quarter, compared to analysts’ expectations of $3.24 billion. Henry Schein had a net margin of 2.51% and a return on equity of 12.90%. The business’s quarterly revenue was up .4% compared to the same quarter last year. During the same period last year, the firm posted $1.32 earnings per share. Equities research analysts forecast that Henry Schein, Inc. will post 4.78 earnings per share for the current fiscal year.

Insider Transactions at Henry Schein

In related news, SVP Lorelei Mcglynn sold 21,035 shares of the business’s stock in a transaction on Friday, September 6th. The shares were sold at an average price of $69.30, for a total value of $1,457,725.50. Following the sale, the senior vice president now directly owns 71,833 shares of the company’s stock, valued at approximately $4,978,026.90. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders own 1.14% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have weighed in on HSIC. StockNews.com raised shares of Henry Schein from a “sell” rating to a “hold” rating in a research note on Thursday, November 7th. Robert W. Baird decreased their price target on shares of Henry Schein from $92.00 to $82.00 and set an “outperform” rating on the stock in a research note on Wednesday, August 7th. UBS Group decreased their price target on shares of Henry Schein from $75.00 to $72.00 and set a “neutral” rating on the stock in a research note on Wednesday, August 7th. Evercore ISI increased their price target on shares of Henry Schein from $70.00 to $74.00 and gave the company an “in-line” rating in a research note on Tuesday, October 8th. Finally, JPMorgan Chase & Co. decreased their price target on shares of Henry Schein from $88.00 to $80.00 and set an “overweight” rating on the stock in a research note on Monday, August 12th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $77.50.

Henry Schein Company Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.